Weight Loss Drugs: Striking the Balance Between Benefits and Risks
Abstract
How to cite this article:
Raja D. Weight Loss Drugs: Striking the Balance Between Benefits and Risks. Chettinad Health City Med J. 2024;13(2):1-3.
DOI: https://doi.org/10.24321/2278.2044.202421
References
Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187-94. [PubMed] [Google Scholar]
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SO, Garvey WT; STEP3 Investigators. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-13. [PubMed] [Google Scholar]
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-61.[PubMed] [Google Scholar]
Hendricks EJ. Off-label drugs for weight management. Diabetes Metab Syndr Obes. 2017;10:223-34. [PubMed] [Google Scholar]
Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebocontrolled, phase 3 trial. Lancet. 2011;377(9774):1341-52. [PubMed] [Google Scholar]
